Abstract
Analysis of data derived from the Alzheimer's Disease Neuroimaging Initiative (ADNI) program showed plasma leptin levels in individuals with Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD) to be lower than those of subjects with normal cognition (NC). Approximately 70% of both men and women with MCI have plasma leptin levels lower than the median values of NC. Additionally, half of these subjects carry at least one apolipoprotein-E4 (APOE-ε4) allele. A subgroup of participants also had cerebrospinal fluid (CSF) leptin measured. Plasma leptin typically reflected the levels of leptin in CSF in all groups (Control/MCI/AD) in both genders. The data suggest that plasma leptin deficiency provides an indication of potential CNS leptin deficiency, further supporting the exploration of plasma leptin as a diagnostic marker for MCI or AD. The important question is whether leptin deficiency plays a role in the causation of AD and/or its progression. If this is the case, individuals with early AD or MCI with low plasma leptin may benefit from leptin replacement therapy. Thus, these data indicate that trials of leptin in low leptin MCI/early-stage AD patients should be conducted to test the hypothesis.
Keywords: Alzheimer's disease neuroimaging initiative, Alzheimer's disease, apolipoprotein-E, leptin replacement, leptin, mild cognitive impairment.
Current Alzheimer Research
Title:Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential
Volume: 11 Issue: 2
Author(s): Jane M. Johnston, William T. Hu, David W. Fardo, Steven J. Greco, George Perry, Thomas J. Montine, John Q. Trojanowski, Leslie M. Shaw, J. Wesson Ashford and Nikolaos Tezapsidis
Affiliation:
Keywords: Alzheimer's disease neuroimaging initiative, Alzheimer's disease, apolipoprotein-E, leptin replacement, leptin, mild cognitive impairment.
Abstract: Analysis of data derived from the Alzheimer's Disease Neuroimaging Initiative (ADNI) program showed plasma leptin levels in individuals with Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD) to be lower than those of subjects with normal cognition (NC). Approximately 70% of both men and women with MCI have plasma leptin levels lower than the median values of NC. Additionally, half of these subjects carry at least one apolipoprotein-E4 (APOE-ε4) allele. A subgroup of participants also had cerebrospinal fluid (CSF) leptin measured. Plasma leptin typically reflected the levels of leptin in CSF in all groups (Control/MCI/AD) in both genders. The data suggest that plasma leptin deficiency provides an indication of potential CNS leptin deficiency, further supporting the exploration of plasma leptin as a diagnostic marker for MCI or AD. The important question is whether leptin deficiency plays a role in the causation of AD and/or its progression. If this is the case, individuals with early AD or MCI with low plasma leptin may benefit from leptin replacement therapy. Thus, these data indicate that trials of leptin in low leptin MCI/early-stage AD patients should be conducted to test the hypothesis.
Export Options
About this article
Cite this article as:
Johnston M. Jane, Hu T. William, Fardo W. David, Greco J. Steven, Perry George, Montine J. Thomas, Trojanowski Q. John, Shaw M. Leslie, Ashford Wesson J. and Tezapsidis Nikolaos, Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential, Current Alzheimer Research 2014; 11 (2) . https://dx.doi.org/10.2174/1567205010666131212114156
DOI https://dx.doi.org/10.2174/1567205010666131212114156 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug
Current Chemical Biology The Yin and Yang of Antiviral Innate Immunity in Central Nervous System
Current Pharmaceutical Design Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire
Current Alzheimer Research Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Current Alzheimer Research Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Athanasios Koukopoulos' Psychiatry: The Primacy of Mania and the Limits of Antidepressants
Current Neuropharmacology Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Olfactory Dysfunction and Cognitive Impairment in Age-Related Neurodegeneration: Prevalence Related to Patient Selection, Diagnostic Criteria and Therapeutic Treatment of Aged Clients Receiving Clinical Neurology and Community-Based Care
Current Clinical Pharmacology Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease
Central Nervous System Agents in Medicinal Chemistry Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease
Current Alzheimer Research Maintaining Plasma Fibrinogen Levels and Fibrinogen Replacement Therapies for Treatment of Intracranial Hemorrhage
Current Drug Targets Is Brain-Derived Neurotrophic Factor: A Common Link Between Neurodegenerative Disorders and Cancer?
Current Alzheimer Research Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Preface
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Importance of Stereochemistry on the Actions of Vitamin D
Current Topics in Medicinal Chemistry Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Current Alzheimer Research